AllAnalyst Report
logoMorningstarSeptember 14, 2020

Seagen Inc.: Narrow-Moat Seattle Genetics Scores Oncology Deals With Merck; Raising FVE to $138

Current Price
Fair Value
Economic Moat

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE

Analyst Profile

Anna Baran

Equity Analyst
Anna Baran is an equity analyst on the healthcare team for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc.Before joining Morningstar in 2016, Baran completed a research project in oncology at the Feinberg School of Medicine and another research thesis in neurobiology at Northwestern University. Before moving to her current role in February 2018, she was on the global and managed portfolios service teams at Morningstar.Baran holds a bachelor’s degree in economics and biological sciences from Northwestern University. She is also a Level II candidate in the Chartered Financial Analyst® program.